Cancer CellCancer BiologyPeer-reviewed journal article
Natural language processing charts transcriptome evolution to design combination cancer therapies
Amir Jassim, Birgit V. NimmervolliD, Sabrina Terranova, Erica Nathan, Linda Hu, Jessica TayloriD, Katherine Elizabeth MasihiD, Lisa Ruff, Matilde Duarte, Elizabeth CooperiD, Gunjan Katyal, Melika AkhbariiD, Reuben J. GilbertsoniD, Jennifer C. ColemaniD, Joseph S. TokeriD, Colton Terhune, Gabriel BalmusiD, Stephen P. JacksoniD, Hailong LiuiD, Tao JiangiD, Michael D. TayloriD, Kui HuaiD, Jean AbrahamiD, Mariella G. FilbiniD, Anthony D. HilliD, , Richard J. GilbertsoniD
Abstract
Combination treatment-the mainstay of cancer therapy-often fails because treatment interactions evoke complex resistance mechanisms that are hard to predict. Designing combination therapy to prevent treatment resistance is especially challenging for rare cancers. Here, we introduce REsistance through COntext DRift (RECODR): a computational pipeline that tracks how genes change their transcriptome context across cancer development and drug treatment conditions. By applying RECODR to a genetically modified mouse model of choroid plexus carcinoma-a rare brain tumour of young children-we identified patterns of transcriptome evolution, cellular heterogeneity and treatment targets that emerged as tumours were initiated and resisted combination treatment. This enabled the prediction of treatment resistance mechanisms and the design of highly effective therapeutic protocols that avoided treatment failure. RECODR can describe complex and dynamic changes in normal and diseased tissues that could be applied to multimodal data from a variety of settings, mitigating treatment resistance across cancers and other diseases.
- organism: mouse
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: drug response / drug discovery
- research focus: differential expression
- approach: deep learning
- approach: statistical model
- Citations
- 15
- FWCI
- 3.41
- Field percentile
- top 6%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Chemoresistome Mapping in Individual Breast Cancer Patients Unravels Diversity in Dynamic Transcriptional Adaptation
M. Dadiani, G. Friedlander, … E. N. Gal-Yam·bioRxiv·Feb 9, 2023
- RWRDC: Predicting Efficacious Drug Combinations in Cancer Based on Random Walk with Restart
Qi Wang, Guiying Yan·bioRxiv·Sep 13, 2020
- Gene expression based inference of drug resistance in cancer
S. Chawla, A. Rockstroh, … D. Sengupta·bioRxiv·Nov 17, 2021
- Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies.
S. A. Wild, I. G. Cannell, … K. Sawicka·bioRxiv·Dec 9, 2021
- CanSeer: A Method for Development and Clinical Translation of Personalized Cancer Therapeutics
Rida Nasir Butt, Amina Bibi, … Safee Ullah Chaudhary·bioRxiv·Jun 29, 2022
- Collateral Responses to Classical Cytotoxic Chemotherapies are Heterogeneous and Sensitivities are Sparse
S. Dalin, D. A. Lauffenburger, M. Hemann·bioRxiv·Apr 15, 2021